CA2512434C - Sustained-release pharmaceutical composition comprising carrageenan for lung administration - Google Patents

Sustained-release pharmaceutical composition comprising carrageenan for lung administration Download PDF

Info

Publication number
CA2512434C
CA2512434C CA2512434A CA2512434A CA2512434C CA 2512434 C CA2512434 C CA 2512434C CA 2512434 A CA2512434 A CA 2512434A CA 2512434 A CA2512434 A CA 2512434A CA 2512434 C CA2512434 C CA 2512434C
Authority
CA
Canada
Prior art keywords
carrageenan
pharmacologically active
active substance
pharmaceutical composition
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2512434A
Other languages
English (en)
French (fr)
Other versions
CA2512434A1 (en
Inventor
Akira Yamamoto
Keigo Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CA2512434A1 publication Critical patent/CA2512434A1/en
Application granted granted Critical
Publication of CA2512434C publication Critical patent/CA2512434C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2512434A 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition comprising carrageenan for lung administration Expired - Fee Related CA2512434C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003049019 2003-02-26
JP2003-049019 2003-02-26
PCT/JP2004/002193 WO2004075920A1 (ja) 2003-02-26 2004-02-25 経肺投与用徐放性製剤学的組成物

Publications (2)

Publication Number Publication Date
CA2512434A1 CA2512434A1 (en) 2004-09-10
CA2512434C true CA2512434C (en) 2012-01-03

Family

ID=32923305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2512434A Expired - Fee Related CA2512434C (en) 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition comprising carrageenan for lung administration

Country Status (9)

Country Link
US (1) US20060078504A1 (cg-RX-API-DMAC10.html)
EP (1) EP1600170A4 (cg-RX-API-DMAC10.html)
JP (1) JPWO2004075920A1 (cg-RX-API-DMAC10.html)
KR (1) KR20050105490A (cg-RX-API-DMAC10.html)
CN (1) CN1744917B (cg-RX-API-DMAC10.html)
CA (1) CA2512434C (cg-RX-API-DMAC10.html)
MY (1) MY142361A (cg-RX-API-DMAC10.html)
TW (1) TW200500085A (cg-RX-API-DMAC10.html)
WO (1) WO2004075920A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150810A1 (en) * 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
SI2178533T1 (sl) * 2007-08-24 2013-07-31 Marinomed Biotechnologie Gmbh Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan
DK2303287T3 (en) * 2008-07-01 2014-02-17 Marinomed Biotechnologie Gmbh Antiallergic marine biopolymers
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
WO1993025193A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Preparation pharmaceutique destinee a etre administree par les voies respiratoires
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
JP2000070327A (ja) * 1998-09-01 2000-03-07 Kao Corp 鼻腔内洗浄具
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
NL1015288C2 (nl) * 2000-05-24 2001-12-14 Peter Ferdinand Elbers Preparaat voor het stabiliseren van de beschermlaag op het epitheel van het hoornvlies of de longblaasjes.
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2002255852A (ja) * 2001-03-01 2002-09-11 Toa Eiyo Ltd 口内炎用スプレー製剤
AU2002249046A1 (en) * 2001-04-23 2002-11-05 Nucryst Pharmaceuticals Corp. Lubricious coatings for substrates
JP2003040766A (ja) * 2001-07-26 2003-02-13 Kao Corp 鼻腔内洗浄具

Also Published As

Publication number Publication date
TWI332403B (cg-RX-API-DMAC10.html) 2010-11-01
MY142361A (en) 2010-11-30
TW200500085A (en) 2005-01-01
HK1083768A1 (zh) 2006-07-14
KR20050105490A (ko) 2005-11-04
CN1744917A (zh) 2006-03-08
CN1744917B (zh) 2010-05-05
WO2004075920A1 (ja) 2004-09-10
JPWO2004075920A1 (ja) 2006-06-01
EP1600170A4 (en) 2010-12-29
EP1600170A1 (en) 2005-11-30
US20060078504A1 (en) 2006-04-13
CA2512434A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
EP1734938B1 (en) Insulin highly respirable microparticles
Liu et al. Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: In vitro and in vivo evaluation
AU718593B2 (en) Polysaccharide microspheres for the pulmonary delivery of drugs
US9155699B2 (en) Pulmonary delivery for levodopa
EP1210069B1 (en) Large porous particles obtainable by spray-drying and suitable for pulmonary administration
JP2009532489A (ja) 薬剤微粒子
US7252840B1 (en) Use of simple amino acids to form porous particles
EP1259228B1 (en) Therapeutic compositions for pulmonary delivery
EP1600170A1 (en) Sustained-release pharmaceutical composition for lung administration
HK1083768B (en) Sustained-release pharmaceutical composition for lung administration
EP1857114A1 (en) Particle and preparation containing the particle
CN121648089A (zh) 一种缓释的西维来司他组合物及其制备方法
AU2006236049A1 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140225